Literature DB >> 332431

Unconjugated hyperbilirubinemia in very low birth weight infants.

K Lee, L M Gartner, A I Eidelman, S Ezhuthachan.   

Abstract

In very low birth weight infants, the occurrence of bilirubin-related brain damage has been repeatedly observed at low serum bilirubin concentrations in close association with altered pathophysiologic status (hypoxia, acidosis, hypothermia, and so on). This increased susceptibility is accompanied by increased severity and duration of unconjugated hyperbilirubinemia as compared with more mature infants. Clinical manifestations of kernicterus in very low birth weight infants are almost always nonspecific. No single biochemical or physiologic measurement is sufficient to predict the risk for development of the bilirubin-related brain damage in this group. Prevention of bilirubin-related brain damage in very low birth weight infants requires not only the maintenance of physiologic and biochemical milieu within normal limits, but also specific therapy to alleviate unconjugated hyperbilirubinemia. Although exchange transfusion has been the mainstay of therapy for unconjugated hyperbilirubinemia, the increased morbidity and mortality associated with exchange transfusion in these immature infants and the need to maintain very low serum bilirubin concentrations suggest that prophylactic phototherapy may be more beneficial for this group.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 332431

Source DB:  PubMed          Journal:  Clin Perinatol        ISSN: 0095-5108            Impact factor:   3.430


  2 in total

1.  A long-term study of hearing in children following neonatal hyperbilirubinemia.

Authors:  J Thoma; G Gerull; D Mrowinski
Journal:  Arch Otorhinolaryngol       Date:  1986

2.  Newborn Metabolic Profile Associated with Hyperbilirubinemia With and Without Kernicterus.

Authors:  Molly E McCarthy; Scott P Oltman; Rebecca J Baer; Kelli K Ryckman; Elizabeth E Rogers; Martina A Steurer-Muller; John S Witte; Laura L Jelliffe-Pawlowski
Journal:  Clin Transl Sci       Date:  2018-10-28       Impact factor: 4.689

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.